Union européenne - letton - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - imūnsupresanti - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Union européenne - letton - EMA (European Medicines Agency)

argenx - efgartigimod alfa - myasthenia gravis - imūnsupresanti - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.